GeriJoy Announces CARES® Dementia Training and Alzheimer's Association ... PR Web (press release) GeriJoy announced today that all GeriJoy caregiving staff are now certified in dementia care by the Alzheimer's Association, through the essentiALZ® certification process. GeriJoy's global care team provides 24/7 companionship, supervision, and care ... |
Month: December 2014
Inner Poet: How Poetry Helps People With Dementia – U.S. News & World Report
Inner Poet: How Poetry Helps People With Dementia U.S. News & World Report People who suffer from dementia and Alzheimer's disease are constantly reminded of the things they may not remember – from what time to take their medications, to what they once did to make a living, to who their own children are. It's hard to imagine ... |
UAB Opens First Alzheimer’s Risk Assessment and Intervention Clinic in US – Alzheimer’s News Today
Alzheimer's News Today | UAB Opens First Alzheimer's Risk Assessment and Intervention Clinic in US Alzheimer's News Today dementia The head of the Division of Memory Disorders of the University of Alabama at Birmingham (UAB), neurologist David Geldmacher, M.D. recently created the UAB Alzheimer's Risk Assessment and Intervention Clinic, which is the first of its kind in ... |
New Combo Drug Approved for Alzheimer’s Dementia – Monthly Prescribing Reference
New Combo Drug Approved for Alzheimer's Dementia Monthly Prescribing Reference Actavis and Adamas announced that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric (memantine HCl extended-release and donepezil HCl) capsules for the treatment of moderate to severe Alzheimer's ... |
Alzheimer’s, in the Open – New York Times
Alzheimer's, in the Open New York Times Frank Bruni would have been heartened to read the many articles reporting the decline in dementia rates (including Alzheimer's) in developed countries. Based on estimates from the Framingham study, a 60-year-old in the United States today has about 44 ... Helping someone in the early stages Of Alzheimer's Disease Alzheimer's Association to host “Living with Alzheimer's disease” series |
The Dementia that is NOT Alzheimer’s Disease – EGP News
The Dementia that is NOT Alzheimer's Disease EGP News Dementia experts are more experienced at differentiating between dementia types. Alzheimer's disease affects cognitive function, including making new experiences into memories. The disorder in LBD affects different aspects of cognition, such as problem ... |
Dr. Shayesteh: Ways to slow Alzheimer’s Disease – WKBN.com
Dr. Shayesteh: Ways to slow Alzheimer's Disease WKBN.com Dr. Shayesteh said there are ways to slow down and even reverse the disease as well as dementia through diet and exercise. He said new research using human subjects shows nutritional and lifestyle changes can prevent or slow some of the early signs of ... |
Alzheimer’s Combo Treatment OKd by FDA – Newsmax Health
Alzheimer's Combo Treatment OKd by FDA Newsmax Health The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis and Adamas Pharmaceuticals. Adamas shares were up nearly 17 percent at $17.10 in premarket trading. The drug, Namzaric is ... |
UPDATE 1-Actavis, Adamas win FDA approval for Alzheimer’s drug – Reuters
Pharmaceutical Business Review | UPDATE 1-Actavis, Adamas win FDA approval for Alzheimer's drug Reuters (Adds details, background, share). Dec 24 (Reuters) - The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc. Adamas shares were up nearly 17 ... Actavis, Adamas Pharma Win FDA Approval For Alzheimer's Drug Namzaric Actavis Alzheimers Drug Approved; Bystolic Gets CRL Actavis, Adamas win FDA approval for Alzheimer's drug |
Actavis, Adamas win FDA approval for Alzheimer’s drug – Reuters
Pharmaceutical Business Review | Actavis, Adamas win FDA approval for Alzheimer's drug Reuters (Reuters) - The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc. Adamas shares were up nearly 17 percent at $17.10 in premarket trading. Actavis, Adamas Pharma Win FDA Approval For Alzheimer's Drug Namzaric |